Hiromi Murata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiromi Murata has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Hidetaka Okada
Department of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Japan
9 shared publications - Susumu Tanaka
Department of Nutrition Science, University of Nagasaki, Siebold, Nagasaki 851-2195, Japan
7 shared publications Naoko Kida
Kansai Medical University, Japan
4 shared publicationsYoji Hisamatsu
Department of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Osaka, Japan
4 shared publicationsHidetaka Okada
Kansai Medical University, Japan
3 shared publicationsHiroaki Tsubokura
Department of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Osaka, Japan
3 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Springer Nature in BMC Ophthalmology
Sterile neutrophilic pseudomembranous conjunctivitis associated with tisotumab vedotin: clinical and cytological evidence from two cases
Background: Tisotumab vedotin-tfTV (TV), an antibody-drug conjugate (ADC), represents a significant advancement in cancer therapy but carries the potential to induce ocular surface toxicity. Having encountered ocular side effects with TV and obtained intriguing findings from histological examination, we discuss the pathophysiology and management approaches. Cases: Two female patients with advanced cervical cancer receiving TV therapy developed pseudomembranous conjunctivitis after 2 to 3 doses. Both cases presented with conjunctival hyperemia and pseudomembrane formation on the tarsal conjunctiva. One case additionally exhibited multiple epithelial erosions on the inferior conjunctiva. Cytology of the pseudomembrane showed neutrophilic infiltration but no detectable microorganisms. This suggested an immune-mediated erosion, such as a tissue factor-mediated reaction in the conjunctival epithelium. Complete remission was achieved within two weeks with topical corticosteroids (dexamethasone eye drops: 4–5 times daily) and lubricants. In both cases, after achieving grade 0 by extending the treatment interval, re-treatment was performed; however, ocular side effects recurred in Case 1. Four days of prophylactic steroid eye drops failed to prevent side effects, but intensifying steroid eye drops allowed inflammation to resolve without sequelae. Nevertheless, intraocular pressure increased after the seventh dose. In Case 2, after side effects appeared, TV administration was resumed with extended intervals and reduced dosage; no conjunctivitis side effects were observed under the recommended prophylactic protocol. Both patients have now completed the seventh dose. Conclusions: TV may cause pseudomembranous conjunctivitis with conjunctival erosion characterized by non-infectious neutrophilic infiltration, suggesting off-target cytotoxicity. Further case accumulation is necessary for the appropriate management of TV-induced ophthalmic side effects.
- 10 September 2026
- Published by Springer Nature in BMC Ophthalmology
Open AccessSterile neutrophilic pseudomembranous conjunctivitis associated with tisotumab vedotin: clinical and cytological evidence from two cases
Background: Tisotumab vedotin-tfTV (TV), an antibody-drug conjugate (ADC), represents a significant advancement in cancer therapy but carries the potential to induce ocular surface toxicity. Having encountered ocular side effects with TV and obtained intriguing findings from histological examination, we discuss the pathophysiology and management approaches. Cases: Two female patients with advanced cervical cancer receiving TV therapy developed pseudomembranous conjunctivitis after 2 to 3 doses. Both cases presented with conjunctival hyperemia and pseudomembrane formation on the tarsal conjunctiva. One case additionally exhibited multiple epithelial erosions on the inferior conjunctiva. Cytology of the pseudomembrane showed neutrophilic infiltration but no detectable microorganisms. This suggested an immune-mediated erosion, such as a tissue factor-mediated reaction in the conjunctival epithelium. Complete remission was achieved within two weeks with topical corticosteroids (dexamethasone eye drops: 4–5 times daily) and lubricants. In both cases, after achieving grade 0 by extending the treatment interval, re-treatment was performed; however, ocular side effects recurred in Case 1. Four days of prophylactic steroid eye drops failed to prevent side effects, but intensifying steroid eye drops allowed inflammation to resolve without sequelae. Nevertheless, intraocular pressure increased after the seventh dose. In Case 2, after side effects appeared, TV administration was resumed with extended intervals and reduced dosage; no conjunctivitis side effects were observed under the recommended prophylactic protocol. Both patients have now completed the seventh dose. Conclusions: TV may cause pseudomembranous conjunctivitis with conjunctival erosion characterized by non-infectious neutrophilic infiltration, suggesting off-target cytotoxicity. Further case accumulation is necessary for the appropriate management of TV-induced ophthalmic side effects.
- Open Access
- 15 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab
Purpose: The combination of lenvatinib plus pembrolizumab (LP) is a standard treatment for advanced or recurrent endometrial cancer. However, the optimal starting dose of lenvatinib is debated due to its toxicity profile. This study aimed to evaluate the effectiveness and safety of the LP regimen in a real-world setting and to investigate the impact of the lenvatinib starting dose on survival outcomes. Methods: We conducted a retrospective analysis of 33 patients with advanced or recurrent endometrial cancer treated with the LP regimen at Kansai Medical University Hospital between February 2022 and August 2025. We evaluated the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Prognostic factors for survival were identified using the Kaplan-Meier method and Cox proportional hazards models. Results: The median follow-up was 27.6 months. The ORR was 48.5%, with a median PFS of 6.7 months and a median OS of 21.7 months. In exploratory multivariable analysis adjusting for age ≥ 75 years and ECOG PS ≥ 1 , a lenvatinib starting dose < 20 mg (vs. 20 mg) was associated with shorter PFS (aHR 5.83; 95% CI 1.84–18.43; p = 0.003). In contrast, peritoneal metastasis (present vs. absent) was independently associated with shorter OS (aHR 7.51; 95% CI 1.87–30.25; p = 0.005). Conclusion: In this real-world cohort, LP therapy was effective and tolerable. In exploratory analyses, lenvatinib starting dose and peritoneal metastasis showed distinct associations with PFS and OS, respectively; however, non-random dose selection and baseline imbalances limit causal interpretation. These findings should be considered hypothesis-generating and warrant prospective validation, particularly for patients with peritoneal metastasis.
- 15 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessImpact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab
Purpose: The combination of lenvatinib plus pembrolizumab (LP) is a standard treatment for advanced or recurrent endometrial cancer. However, the optimal starting dose of lenvatinib is debated due to its toxicity profile. This study aimed to evaluate the effectiveness and safety of the LP regimen in a real-world setting and to investigate the impact of the lenvatinib starting dose on survival outcomes. Methods: We conducted a retrospective analysis of 33 patients with advanced or recurrent endometrial cancer treated with the LP regimen at Kansai Medical University Hospital between February 2022 and August 2025. We evaluated the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Prognostic factors for survival were identified using the Kaplan-Meier method and Cox proportional hazards models. Results: The median follow-up was 27.6 months. The ORR was 48.5%, with a median PFS of 6.7 months and a median OS of 21.7 months. In exploratory multivariable analysis adjusting for age ≥ 75 years and ECOG PS ≥ 1 , a lenvatinib starting dose < 20 mg (vs. 20 mg) was associated with shorter PFS (aHR 5.83; 95% CI 1.84–18.43; p = 0.003). In contrast, peritoneal metastasis (present vs. absent) was independently associated with shorter OS (aHR 7.51; 95% CI 1.87–30.25; p = 0.005). Conclusion: In this real-world cohort, LP therapy was effective and tolerable. In exploratory analyses, lenvatinib starting dose and peritoneal metastasis showed distinct associations with PFS and OS, respectively; however, non-random dose selection and baseline imbalances limit causal interpretation. These findings should be considered hypothesis-generating and warrant prospective validation, particularly for patients with peritoneal metastasis.
- Open Access
- 1 July 2025
- Published by MDPI AG in Nutraceuticals
- Vol. 5 (3) , 16
Regulatory Mechanism of Human Endometrial Stromal Cell Decidualization by Ergothioneine
Endometrial stromal cells (EnSCs) undergo decidualization in response to progesterone. Decidualization facilitates spiral artery remodeling, immune tolerance in the endometrium, and fetal cell invasion and placentation—all essential for successful embryo implantation. Therefore, we aimed to investigate whether ergothioneine (EGT) plays a role in reproduction, particularly in decidualization and implantation. In this study, we found that solute carrier family 22 member 4 (SLC22A4), a specific transporter of EGT—a functional food ingredient with strong anti-aging properties—is upregulated in decidualized EnSCs. The effects of EGT were examined using uterine tissues from patients, primary cultured EnSCs, EnSC cell lines, and co-cultures with a fetal cell line. We observed a significant increase in SLC22A4 expression in secretory-phase human uterine tissue, decidualized EnSCs, and EnSC cell lines. We also found that EGT regulates insulin-like growth factor binding protein 1 expression, which promotes placentation. In co-cultures of EnSC and fetal cell lines, EGT upregulated ectonucleoside triphosphate diphosphohydrolase 1 and major histocompatibility complex, class I, G expression in fetal cell lines—both critical for placentation. These findings suggest that EGT is crucial to regulating decidualization and its markers, particularly insulin-like growth factor-binding protein 1, which contributes to placentation.
- 1 July 2025
- Published by MDPI AG in Nutraceuticals
- Vol. 5 (3) , 16
Open AccessRegulatory Mechanism of Human Endometrial Stromal Cell Decidualization by Ergothioneine
Endometrial stromal cells (EnSCs) undergo decidualization in response to progesterone. Decidualization facilitates spiral artery remodeling, immune tolerance in the endometrium, and fetal cell invasion and placentation—all essential for successful embryo implantation. Therefore, we aimed to investigate whether ergothioneine (EGT) plays a role in reproduction, particularly in decidualization and implantation. In this study, we found that solute carrier family 22 member 4 (SLC22A4), a specific transporter of EGT—a functional food ingredient with strong anti-aging properties—is upregulated in decidualized EnSCs. The effects of EGT were examined using uterine tissues from patients, primary cultured EnSCs, EnSC cell lines, and co-cultures with a fetal cell line. We observed a significant increase in SLC22A4 expression in secretory-phase human uterine tissue, decidualized EnSCs, and EnSC cell lines. We also found that EGT regulates insulin-like growth factor binding protein 1 expression, which promotes placentation. In co-cultures of EnSC and fetal cell lines, EGT upregulated ectonucleoside triphosphate diphosphohydrolase 1 and major histocompatibility complex, class I, G expression in fetal cell lines—both critical for placentation. These findings suggest that EGT is crucial to regulating decidualization and its markers, particularly insulin-like growth factor-binding protein 1, which contributes to placentation.
- Open Access
- 26 April 2024
- Published by MDPI AG in Reproductive Medicine
- Vol. 5 (2) , 43-56
IL17A Suppresses IGFBP1 in Human Endometrial Stromal Cells
Interleukin (IL) 17A has been implicated in preeclampsia, preterm labor, and miscarriage. IL17A production in non-lymphoid tissues is mainly carried out by unconventional γδ17T cells. Innate lymphoid cells (ILCs) 3, a subgroup of innate lymphocytes, can also be a source of IL17A in the endometrium and are required from implantation to early pregnancy, with their regulation ensuring that pregnancy continues. Herein, we examined the expression of γδ17T cells and ILC3 regulators IL1B, IL23A, and IL17D and IL17A receptors (IL17RA/IL17RC) in human endometrial stromal cells (EnSCs) and cell lines (KC02-44D). Accordingly, quantitative polymerase chain reaction and immunoblotting were employed. IL1B, IL23A, and IL17D were significantly upregulated in decidualized EnSCs and KC02-44D cells. A significant augmentation in IL17RA/IL17RC was also observed in decidualization. IL17A stimulation of KC02-44D cells during decidualization suppressed the decidualization marker IGFBP1. The involvement of transcription factor Forkhead box protein O1 (FOXO1) in this repression was reflected by its translocation from the nucleus into the cytoplasm. A role for IkB kinase alpha in FOXO1 phosphorylation-mediated migration was also suggested. Taken together, our findings indicate that the secretion of IL17A by γδ17T and ILC3 cells in the uterus contributes to EnSCs function and may play critical roles in regulating IGFBP1-mediated implantation and fetal growth.
- 26 April 2024
- Published by MDPI AG in Reproductive Medicine
- Vol. 5 (2) , 43-56
Open AccessIL17A Suppresses IGFBP1 in Human Endometrial Stromal Cells
Interleukin (IL) 17A has been implicated in preeclampsia, preterm labor, and miscarriage. IL17A production in non-lymphoid tissues is mainly carried out by unconventional γδ17T cells. Innate lymphoid cells (ILCs) 3, a subgroup of innate lymphocytes, can also be a source of IL17A in the endometrium and are required from implantation to early pregnancy, with their regulation ensuring that pregnancy continues. Herein, we examined the expression of γδ17T cells and ILC3 regulators IL1B, IL23A, and IL17D and IL17A receptors (IL17RA/IL17RC) in human endometrial stromal cells (EnSCs) and cell lines (KC02-44D). Accordingly, quantitative polymerase chain reaction and immunoblotting were employed. IL1B, IL23A, and IL17D were significantly upregulated in decidualized EnSCs and KC02-44D cells. A significant augmentation in IL17RA/IL17RC was also observed in decidualization. IL17A stimulation of KC02-44D cells during decidualization suppressed the decidualization marker IGFBP1. The involvement of transcription factor Forkhead box protein O1 (FOXO1) in this repression was reflected by its translocation from the nucleus into the cytoplasm. A role for IkB kinase alpha in FOXO1 phosphorylation-mediated migration was also suggested. Taken together, our findings indicate that the secretion of IL17A by γδ17T and ILC3 cells in the uterus contributes to EnSCs function and may play critical roles in regulating IGFBP1-mediated implantation and fetal growth.
- Open Access
- 10 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1275
The Regulators of Human Endometrial Stromal Cell Decidualization
Several factors are important for implantation and subsequent placentation in the endometrium, including immunity, angiogenesis, extracellular matrix, glucose metabolism, reactive oxidative stress, and hormones. The involvement or abnormality of these factors can impair canonical decidualization. Unusual decidualization can lead to perinatal complications, such as disruption of trophoblast invasion. Drastic changes in the morphology and function of human endometrial stromal cells (hESCs) are important for decidualization of the human endometrium; hESCs are used to induce optimal morphological and functional decidualization in vitro because they contain estrogen and progesterone receptors. In this review, we will focus on the studies that have been conducted on hESC decidualization, including the results from our laboratory.
- 10 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1275
Open AccessThe Regulators of Human Endometrial Stromal Cell Decidualization
Several factors are important for implantation and subsequent placentation in the endometrium, including immunity, angiogenesis, extracellular matrix, glucose metabolism, reactive oxidative stress, and hormones. The involvement or abnormality of these factors can impair canonical decidualization. Unusual decidualization can lead to perinatal complications, such as disruption of trophoblast invasion. Drastic changes in the morphology and function of human endometrial stromal cells (hESCs) are important for decidualization of the human endometrium; hESCs are used to induce optimal morphological and functional decidualization in vitro because they contain estrogen and progesterone receptors. In this review, we will focus on the studies that have been conducted on hESC decidualization, including the results from our laboratory.
- Open Access
- 26 November 2021
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 43 (3) , 2111-2123
Matrix Metalloproteinases in Human Decidualized Endometrial Stromal Cells
Cyclic changes, such as growth, decidualization, shedding, and regeneration, in the human endometrium are regulated by the reciprocal action of female hormones, such as estradiol (E2), and progesterone (P4). Matrix metalloproteases (MMPs) and tissue inhibitors of MMPs (TIMPs) control the invasion of extravillous trophoblast cells after implantation. Several MMPs and TIMPs function in the decidua and endometrial stromal cells (ESCs). Here, we aimed to systematically investigate the changes in MMPs and TIMPs associated with ESC decidualization. We evaluated the expression of 23 MMPs, four TIMPs, and four anti-sense non-coding RNAs from MMP loci. Primary ESC cultures treated with E2 + medroxyprogesterone acetate (MPA), a potent P4 receptor agonist, showed significant down-regulation of MMP3, MMP10, MMP11, MMP12, MMP20, and MMP27 in decidualized ESCs, as assessed by quantitative reverse transcription PCR. Further, MMP15 and MMP19 were significantly upregulated in decidualized ESCs. siRNA-mediated silencing of Heart and Neural Crest Derivatives Expressed 2 (HAND2), a master transcriptional regulator in ESC decidualization, significantly increased MMP15 expression in untreated human ESCs. These results collectively indicate the importance of MMP15 and MMP19 in ESC decidualization and highlight the role of HAND2 in repressing MMP15 transcription, thereby regulating decidualization.
- 26 November 2021
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 43 (3) , 2111-2123
Open AccessMatrix Metalloproteinases in Human Decidualized Endometrial Stromal Cells
Cyclic changes, such as growth, decidualization, shedding, and regeneration, in the human endometrium are regulated by the reciprocal action of female hormones, such as estradiol (E2), and progesterone (P4). Matrix metalloproteases (MMPs) and tissue inhibitors of MMPs (TIMPs) control the invasion of extravillous trophoblast cells after implantation. Several MMPs and TIMPs function in the decidua and endometrial stromal cells (ESCs). Here, we aimed to systematically investigate the changes in MMPs and TIMPs associated with ESC decidualization. We evaluated the expression of 23 MMPs, four TIMPs, and four anti-sense non-coding RNAs from MMP loci. Primary ESC cultures treated with E2 + medroxyprogesterone acetate (MPA), a potent P4 receptor agonist, showed significant down-regulation of MMP3, MMP10, MMP11, MMP12, MMP20, and MMP27 in decidualized ESCs, as assessed by quantitative reverse transcription PCR. Further, MMP15 and MMP19 were significantly upregulated in decidualized ESCs. siRNA-mediated silencing of Heart and Neural Crest Derivatives Expressed 2 (HAND2), a master transcriptional regulator in ESC decidualization, significantly increased MMP15 expression in untreated human ESCs. These results collectively indicate the importance of MMP15 and MMP19 in ESC decidualization and highlight the role of HAND2 in repressing MMP15 transcription, thereby regulating decidualization.
- 28 September 2021
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 27 (11)
Transcriptional regulation of LGALS9 by HAND2 and FOXO1 in human endometrial stromal cells in women with regular cycles
Uterine natural killer cells are regulated via surface inhibitory receptors for IL15 and galectin-9 (LGALS9) secreted by endometrial stromal cells (ESCs). However, the mechanism that regulates LGALS9 mRNA levels in ESCs is unclear. The aim of this study is to clarify the transcriptional regulation of LGALS9 in ESCs. Here, LGALS9 mRNA expression levels significantly decreased in the endometrial tissue in the early- to mid-secretory phase, and recovered in the mid- to late-secretory phase, compared to that in the proliferative phase. In ESCs, LGALS9 mRNA expression significantly decreased following estradiol + medroxyprogesterone acetate treatment for 1 day and increased after 12 days compared to that in the control. The transcriptional activity of the LGALS9 upstream region was upregulated by heart and neural crest derivatives expressed 2 (HAND2) and downregulated by forkhead box O1 (FOXO1). In ESCs, HAND2 expression significantly increased throughout the 12 days treatment with steroid hormones, whereas FOXO1 expression significantly increased on Day 1, reached a plateau, and significantly increased again after 6 days of treatment. Levels of FOXO1 phosphorylation (pFOXO1) remained unchanged after a 3-day treatment of ESCs with steroid hormones, but significantly increased following a 12-day treatment. pFOXO1 could not bind to the DNA and was thus unable to directly suppress LGALS9 transcription. Therefore, expression level of HAND2 and phosphorylation status of FOXO1 may determine LGALS9 mRNA expression. This study provides a novel molecular mechanism underlying the transcriptional regulation of LGALS9 mRNA in ESCs, which could be valuable in the treatment of diseases associated with decidualization failure.
- 28 September 2021
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 27 (11)
Transcriptional regulation of LGALS9 by HAND2 and FOXO1 in human endometrial stromal cells in women with regular cycles
Uterine natural killer cells are regulated via surface inhibitory receptors for IL15 and galectin-9 (LGALS9) secreted by endometrial stromal cells (ESCs). However, the mechanism that regulates LGALS9 mRNA levels in ESCs is unclear. The aim of this study is to clarify the transcriptional regulation of LGALS9 in ESCs. Here, LGALS9 mRNA expression levels significantly decreased in the endometrial tissue in the early- to mid-secretory phase, and recovered in the mid- to late-secretory phase, compared to that in the proliferative phase. In ESCs, LGALS9 mRNA expression significantly decreased following estradiol + medroxyprogesterone acetate treatment for 1 day and increased after 12 days compared to that in the control. The transcriptional activity of the LGALS9 upstream region was upregulated by heart and neural crest derivatives expressed 2 (HAND2) and downregulated by forkhead box O1 (FOXO1). In ESCs, HAND2 expression significantly increased throughout the 12 days treatment with steroid hormones, whereas FOXO1 expression significantly increased on Day 1, reached a plateau, and significantly increased again after 6 days of treatment. Levels of FOXO1 phosphorylation (pFOXO1) remained unchanged after a 3-day treatment of ESCs with steroid hormones, but significantly increased following a 12-day treatment. pFOXO1 could not bind to the DNA and was thus unable to directly suppress LGALS9 transcription. Therefore, expression level of HAND2 and phosphorylation status of FOXO1 may determine LGALS9 mRNA expression. This study provides a novel molecular mechanism underlying the transcriptional regulation of LGALS9 mRNA in ESCs, which could be valuable in the treatment of diseases associated with decidualization failure.
- Open Access
- 18 January 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (2) , 351
Immune Tolerance of the Human Decidua
The endometrium is necessary for implantation, complete development of the placenta, and a successful pregnancy. The endometrium undergoes repeated cycles of proliferation, decidualization (differentiation), and shedding during each menstrual cycle. The endometrium—including stromal, epithelial, vascular endothelial, and immune cells—is both functionally and morphologically altered in response to progesterone, causing changes in the number and types of immune cells. Immune cells make up half of the total number of endometrial cells during implantation and menstruation. Surprisingly, immune tolerant cells in the endometrium (uterine natural killer cells, T cells, and macrophages) have two conflicting functions: to protect the body by eliminating pathogenic microorganisms and other pathogens and to foster immunological change to tolerate the embryo during pregnancy. One of the key molecules involved in this control is the cytokine interleukin-15 (IL-15), which is secreted by endometrial stromal cells. Recently, it has been reported that IL-15 is directly regulated by the transcription factor heart- and neural crest derivatives-expressed protein 2 in endometrial stromal cells. In this review, we outline the significance of the endometrium and immune cell population during menstruation and early pregnancy and describe the factors involved in immune tolerance and their involvement in the establishment and maintenance of pregnancy.
- 18 January 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (2) , 351
Open AccessImmune Tolerance of the Human Decidua
The endometrium is necessary for implantation, complete development of the placenta, and a successful pregnancy. The endometrium undergoes repeated cycles of proliferation, decidualization (differentiation), and shedding during each menstrual cycle. The endometrium—including stromal, epithelial, vascular endothelial, and immune cells—is both functionally and morphologically altered in response to progesterone, causing changes in the number and types of immune cells. Immune cells make up half of the total number of endometrial cells during implantation and menstruation. Surprisingly, immune tolerant cells in the endometrium (uterine natural killer cells, T cells, and macrophages) have two conflicting functions: to protect the body by eliminating pathogenic microorganisms and other pathogens and to foster immunological change to tolerate the embryo during pregnancy. One of the key molecules involved in this control is the cytokine interleukin-15 (IL-15), which is secreted by endometrial stromal cells. Recently, it has been reported that IL-15 is directly regulated by the transcription factor heart- and neural crest derivatives-expressed protein 2 in endometrial stromal cells. In this review, we outline the significance of the endometrium and immune cell population during menstruation and early pregnancy and describe the factors involved in immune tolerance and their involvement in the establishment and maintenance of pregnancy.
- Open Access
- 1 July 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (28) , 9596-9605
The transcription factor HAND2 up-regulates transcription of the IL15 gene in human endometrial stromal cells
- 1 July 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (28) , 9596-9605
Open AccessThe transcription factor HAND2 up-regulates transcription of the IL15 gene in human endometrial stromal cells